A SEER analysis reports Medicare spending on prostate cancer therapy nearly quadrupled from $504 million to $1.9 billion from 2012–2021, driven largely by second-generation androgen receptor pathway inhibitors which comprised two-thirds (!!) of total spending in 2021, making affordability and realized value an essential part of treatment decision-making alongside survival and quality of life. Can we get a price check on ablative radiation treatments for oligomets on aisle 3? | Shen, JAMA Netw Open 2026
